Saturday, November 1, 2025

Latest

Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Sendero Resources: Marrone’s Next Billion-Dollar Play?

We Don’t Need $5,000 Gold Yet | Sean Roosen – Osisko Development

Prospector Metals: The $82 Million Hole

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

Haywood Reiterates $12 Price Target On Well Health

On January 20th, Well Health (TSX: WELL) provided a business update which included fourth quarter...

Monday, January 24, 2022, 04:22:00 PM

Lundin Mining Sees BMO Maintain Price Target Following Q3 Earnings

Yesterday Lundin Mining (TSX: LUN) reported their third quarter earnings. Third-quarter cash flows were +$272.2...

Thursday, October 29, 2020, 03:29:00 PM

Origin House Secures Additional Short Term Loan

Origin House (CSE: OH) announced this morning that it had secured an additional short term...

Friday, September 20, 2019, 09:51:29 AM

Green Thumb Sees Consensus Estimate Fall To $49.89 After Q4 Earnings

Earlier this week, Green Thumb Industries (CSE: GTII) reported its fourth quarter financial results. The...

Thursday, March 3, 2022, 04:31:00 PM

Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company...

Friday, August 20, 2021, 07:54:00 AM